1. Home
  2. BIAF

as of 08-03-2026 4:00pm EST

$0.60
$0.03
-4.78%
Stocks Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances Nasdaq

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Founded: 2014 Country:
United States
United States
Employees: 57 City: SAN ANTONIO
Market Cap: 4.5M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 298.8K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.23 - $13.50 Next Earning Date: 05-14-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 20.95% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered BIAF Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 72.00%
72.00%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: